Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Accu-Break Pharmaceuticals

Request full access

Accu-break Pharmaceuticals, Inc.

Plantation, United StatesFounded 2001Biotech & Life Sciences

About Accu-Break Pharmaceuticals

Accu-Break Pharmaceuticals, Inc. operates as a privately-held pharmaceutical technology company focused on developing and licensing its patented tablet technologies. Founded in 2001, the firm is headquartered in Hollywood, Florida. The core of Accu-Break's business revolves around its ACCU-BREAK™ family of technologies, which are designed to enhance the functionality and safety of pharmaceutical tablets.

The company's primary innovation is the incorporation of a drug-free layer into a tablet, which serves as a breaking region. This design allows a tablet to be easily and accurately broken into smaller doses without compromising the integrity of the active pharmaceutical ingredient. This addresses a common issue in medicine where patients need to split tablets to adjust their dosage, a practice that can lead to inaccurate dosing and loss of medication mass. The technology is particularly beneficial for medications requiring precise titration or for pediatric and geriatric patients who often need customized doses. Accu-Break has developed several iterations of this technology, including Accu-B, a bilayer tablet, and Accu-T, a five-layer tablet that can also be used to combine incompatible active ingredients in a single pill.

Accu-Break's business model is centered on technology licensing and product development partnerships. The company collaborates with pharmaceutical manufacturers to reformulate existing drugs using its ACCU-BREAK™ technology, thereby creating enhanced products with potential for improved market positioning and extended patent protection. These partnerships provide a revenue stream through licensing agreements. The company has engaged in collaborations to develop products for conditions such as Parkinson's disease and has also licensed its technology for the development of cannabinoid products. In 2012, Accu-Break entered into a development and license agreement with Alembic Pharmaceuticals to create new brand products, with the first target being a version of the anticoagulant warfarin. This collaboration led to the filing of a New Drug Application (NDA) with the U.S. FDA in 2015.

Source: Dealroom company data

At a glance

Founded
2001
Headquarters
Plantation, United States
Sector
Biotech & Life Sciences

Accu-Break Pharmaceuticals in the Plantation ecosystem

Live from Dealroom

The Accu-Break Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Plantation HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Accu-Break Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Accu-Break Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.